Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus

Archives of Dermatology

Volumn 139, Issue 1, 2003, Pages 45-49

  Srivastava, Monika ^a   Rencic, Adrienne ^a   Diglio, Gerardine ^a   Santana, Helen ^a   Bonitz, Paula ^a   Watson, Rosemarie ^a   Ha, Esther ^a   Anhalt, Grant J ^a   Provost, Thomas T ^a   Nousari, Carlos H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIBODY; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA INTERFERON; CALCIUM CHANNEL BLOCKING AGENT; CHLOROTHIAZIDE; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IMMUNOGLOBULIN G; INSULIN; INTERFERON; LEVOTHYROXINE; LISINOPRIL; NIFEDIPINE; PRAVASTATIN; PROPRANOLOL; RO ANTIBODY; SIMVASTATIN; STATINE; TRIAMTERENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ADULT; ARTICLE; CLINICAL ARTICLE; DERMATITIS; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; ERYTHEMA; FEMALE; HEMAGGLUTINATION; HUMAN; IMMUNODIFFUSION; IMMUNOGLOBULIN DEPOSITION; IMMUNOPATHOLOGY; MALE; PHOTOSENSITIVITY DISORDER; PRIORITY JOURNAL; SKIN LUPUS ERYTHEMATOSUS; UNITED STATES;

EID: 0037231631     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.1.45     Document Type: Article

References (42)

1. Provost TT, Watson R, Simmons-O'Brien, E. Significance of the anti-Ro(SS-A) antibody in evaluation of patients with cutaneous manifestations of a connective tissue disease. J Am Acad Dermatol. 1996;35:147-169.
2. Rowell MR, Swanson-Beck J, Anderson JR. Lupus erythematosus and erythema-multiforme-like lesions. Arch Dermatol. 1963;88:176-180.
3. Sontheimer RD, Thomas JR, Gilliam JD. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol. 1979;115:1409-1415.
4. Maddison PJ, Provost TT, Reichlin M. Serologic findings in patients with "ANA negative" SLE. Medicine (Baltimore). 1981;60:87-94.
5. Sontheimer RD, Maddison PJ, Reichlin M, et al. Serologic and HLA associations of subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med. 1982;97:664-671.
6. Provost TT, Levis SS, Watson RM, et al. Detection of anti-Ro(SS-A) antibodies by gel double diffusions and a sandwich ELISA in systemic and subacute cutaneous lupus erythematosus and Sjögren's syndrome. J Autoimmun. 1991;4:87-96.
7. Maddison PJ, Moagavero M, Provost TT, et al. The clinical significance of auto-antibodies to a soluble cytoplasmic antigen in systemic lupus erythematosus and other connective tissue diseases. J Rheumatol. 1979;6:189-195.
8. Synkowski DR, Reichlin M, Provost TT. Serum antibodies in systemic lupus erythematosus and correlation with cutaneous features. J Rheumatol. 1982;9:380-385.
9. Reed BR, Huff JC, Jones SK, Orton PW, Lee LA, Norris DA. Subacute lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med. 1985; 103:49-51.
10. Callen JP. Drug-induced cutaneous lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol. 2001;45:315-316.
11. Herrera-Esparza R, Provost TT, Diaz LA. Molecular characterization of Ro(SSA) and La(SSB) proteins. J Rheumatol. 1986;13:327-330.
12. Merryman P, Louie P. Comparison of assay systems for detecting antibodies to nuclear ribonucleoproteins. J Clin Pathol. 1991;44:685-689.
13. Moore TL, Weiss TD, Neucks SH, Baldassare AR, Zuckner J. Extractable nuclear antigens. Semin Arthritis Rheum. 1981;10:309-318.
14. Monce NM Jr, Bogusky RT, Cappel NN. An enzyme immunoassay screening test for the detection of total antinuclear antibodies. J Clin Lab Anal. 1991;5:439-442.
15. Collins AB, Colvin RB, Nousari HC, Anhalt GJ. Immunofluorescence methods for diagnosis of renal and skin diseases. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical Laboratory Immunology. 6th ed. Washington, DC: American Society of Microbiology Press; 2002:393-402.
16. Nousari HC, Anhalt GJ. Skin diseases. In: Rose NR, Hamilton RG, Detrick B, eds. Manual of Clinical Laboratory Immunology. 6th ed. Washington, DC: American Society of Microbiology Press; 2002:1032-1042.
17. Pramatarov KD. Drug-induced lupus erythematosus. Clin Dermatol. 1998;16: 367-377.
18. Hess E. Drug-related lupus. N Engl J Med. 1988;318:1460-1462.
19. Fine RM. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Int J Dermatol. 1989;28:375-379.
20. Darken M, McBurney EI. Subacute cutaneous lupus erythematosus-like drug eruption due to combination diuretic hydrochlorothiazide and triamterene. J Am Acad Dermatol. 1988;18:38-42.
21. Brown CW Jr, Deng JS. Thiazide diuretics induce cutaneous lupus-like adverse reaction. J Toxicol Clin Toxicol. 1995;33:729-733.
22. Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions [letter]. N Engl J Med. 1995;333:1429.
23. Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol. 1997;28:67-73.
24. Fernandez-Diaz ML, Herranz P, Suarez-Marrero MC, Borbujo J, Manzano R, Casado M. Subacute cutaneous lupus erythematosus associated with cilazapril [letter]. Lancet. 1995;345:398.
25. Nousari HC, KimYai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998;352:1825-1826.
26. Patel GK, Anstey AV. Rifampicin-induced lupus erythematosus. Clin Exp Dermatol. 2001;26:260-262.
27. Miyagawa S, Okuchi T, Shiomi Y, Sakamoto K. Subacute cutaneous lupus erythematosus lesions precipitated by griseofulvin. J Am Acad Dermatol. 1989; 21(2, pt 2):343-346.
28. Brooke R. Terbinafine-induced subacute cutaneous lupus erythematosus [letter]. Br J Dermatol. 1998;139:1132-1133.
29. Bonsmann G, Schiller M, Luger TA, Stander S. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol. 2001;44:925-931.
30. Holmes S, Kemmett D. Exacerbation of systemic lupus erythematosus induced by terbinafine [letter]. Br J Dermatol. 1998;139:1133.
31. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine. Arch Dermatol. 2001;137:1196-1198.
32. Toll A, Campo-Pisa P, Gonzalez-Castro J, et al. Subacute cutaneous lupus erythematosus associated with cinnarizine and thiethylperazine therapy. Lupus. 1998; 7:364-366.
33. McGrath H Jr, Scopelitis E, Nesbitt LT Jr. Subacute cutaneous lupus erythematosus during psoralen ultraviolet A therapy. Arthritis Rheum. 1990;33:302-303.
34. Parodi A, Rivara G, Guarrera M. Possible naproxen-induced relapse of subacute cutaneous lupus erythematosus. JAMA. 1992;268:51-52.
35. Roura M, Lopez-Gil F, Umbert P. Systemic lupus erythematosus exacerbated by piroxicam. Dermatologica 1991;182:56-58.
36. Gange RW, Levene GM. A distinctive eruption in patients receiving oxprenolol. Clin Exp Dermatol. 1979;4:87-97.
37. Shereretz EF. Lichen planus following procainamide-induced lupus erythematosus. Cutis. 1988;42:51-53.
38. LeRoy D, Dompmartin A, Le Jean S, Guillemain JL, Mandard JC, Deschamps P. Dermatitis casued by aldactone of a lupic annular erythema type [in French]. Ann Dermatol Venereol. 1987;114:1237-1240.
39. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am. 1989;73:1073-1090.
40. Schalke BB, Schmidt B, Toyka K, Hartung HP. Pravastatin-asscciated inflammatory myopathy. N Engl J Med. 1992;327:649-650.
41. Hill C, Zeitz C, Kirkham B. Dermatomyositis with lung involvement in a patient treated with simvastatin. Aust N Z J Med. 1995;25:745-746.
42. Khattak FH, Morris IM, Branford WA. Simvastatin-associated dermatomyositis [letter]. Br J Rheumatol. 1994;33:199